Corneal crosslinking (CXL) can be used to treat corneal neovascularization (CNV) if any causative infection is eradicated at the time of treatment or shortly thereafter, according ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

[49] The practitioner should be aware of corneal neovascularization ... fitting contact lenses in patients after myopic surgical treatment because of the central corneal flattening.

The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...

Diabetic retinopathy, a common complication of diabetes, can damage the retina and lead to blindness. Early symptoms like ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

The rare genetic disorder occurs in around 1 in 50,000 births and results in a high quantity of malignant and benign tumors ...

A panelist discusses how dry eye disease involves tear film imbalance, leading to inflammation and ocular surface damage, ...

for the treatment of signs and symptoms of dry eye disease. Approval of Tryptyr was granted to Alcon. Currently, dry eye disease treatment options are limited due to slow therapeutic onset ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

A recent study found that older adults with diabetes who use a GLP-1 drug have double the risk of developing wet age-related ...